Bertocci, Michele A.
Hanford, Lindsay
Manelis, Anna
Iyengar, Satish
Youngstrom, Eric A.
Gill, Mary Kay
Monk, Kelly
Versace, Amelia
Bonar, Lisa
Bebko, Genna
Ladouceur, Cecile D.
Perlman, Susan B
Diler, Rasim
Horwitz, Sarah M.
Arnold, L. Eugene
Hafeman, Danella
Travis, Michael J.
Kowatch, Robert
Holland, Scott K.
Fristad, Mary. A.
Findling, Robert L.
Birmaher, Boris
Phillips, Mary L.
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (2R01 MH73816-09A1, 2R01 MH73801-09A1, 2R01 MH73967-09A1, R01 MH060952-16, 2R01 MH73953-09A1, 2R01 MH73953-09A1)
Article History
Received: 12 March 2018
Revised: 31 July 2018
Accepted: 7 September 2018
First Online: 19 October 2018
Compliance with ethical standards
:
: BB has or will receive royalties from for publications from Random House, Inc (New hope for children and teens with bipolar disorder) and Lippincott Williams & Wilkins (Treating Child and Adolescent Depression). He is employed by the University of Pittsburgh and the University of Pittsburgh Medical Center and receives research funding from NIMH. MLP is a consultant for Roche Pharmaceuticals. LEA has received research funding from Curemark, Forest, Lilly, Neuropharm, Novartis, Noven, Shire, Supernus, and YoungLiving (as well as NIH and Autism Speaks) and has consulted with or been on advisory boards for Arbor, Gowlings, Ironshore, Neuropharm, Novartis, Noven, Organon, Otsuka, Pfizer, Roche, Seaside Therapeutics, Sigma Tau, Shire, Tris Pharma, and Waypoint and received travel support from Noven. RLF receives or has received research support, acted as a consultant and/or served on a speaker’s bureau for Aevi, Akili, Alcobra, Amerex, American Academy of Child & Adolescent Psychiatry, American Psychiatric Press, Bracket, Epharma Solutions, Forest, Genentech, Guilford Press, Ironshore, Johns Hopkins University Press, KemPharm, Lundbeck, Merck, NIH, Neurim, Nuvelution, Otsuka, PCORI, Pfizer, Physicians Postgraduate Press, Purdue, Roche, Sage, Shire, Sunovion, Supernus Pharmaceuticals, Syneurx, Teva, Tris, TouchPoint, Validus, and WebMD. MAF receives royalties from Guilford Press, American Psychiatric Press, and CFPSI. RK is a consultant for Forest Pharmaceutical and the REACH Foundation. He is employed by the Ohio State Wexner Medical Center. EAY has consulted with Pearson, Western Psychological Services, Lundbeck and Otsuka about assessment, as well as having grant support from the NIH. All the remaining authors declare that they have no conflict of interest.